Antibody therapy for pediatric leukemia

Frontiers in Oncology

Volumn 4 APR, Issue , 2014, Pages

  Vedi, Aditi ^a,b   Ziegler, David S ^a,b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Antibodies; Bispecific antibodies; Childhood leukemia; Conjugated antibodies; Monoclonal

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ASPARAGINASE; AVE 9633; BLINATUMOMAB; CALICHEAMICIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DCDT 2980S; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; FIRTECAN; GEMTUZUMAB; GEMTUZUMAB OZOGAMICIN; INOTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; OCRELIZUMAB; OFATUMUMAB; OZOGAMICIN; PREDNISONE; RITUXIMAB; SAR 3419; SGN CD19A; SGN CD33A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDOTIN; VELTUZUMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CYTOTOXICITY; DRUG DOSE ESCALATION; FOLLICULAR LYMPHOMA; HUMAN; IMMUNE SYSTEM; LEUKEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA;

EID: 84901044425     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00082     Document Type: Review

References (79)

1. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol (2005) 131:579-87. doi: 10.1111/j.1365-2141.2005.05773.x.
2. Howlader N, Noone A, Krapcho M. Childhood Cancer SEER Cancer Statistics Review 1975-2010. Memphis, TN: Ash Education (2013).
3. Robison LL. Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0-20 years of age. Hematology Am Soc Hematol Educ Program (2011) 2011:238-42. doi:10.1182/asheducation-2011.1.238.
4. Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood (2005) 106:1183-8. doi:10.1182/blood-2004-10-3821.
5. Pratt W, Ruddon R, Ensminger W. The Anticancer Drugs. 2nd ed. Oxford, UK: Oxford University Press (1994). p. 69-168.
6. Goldmacher VS, Kovtun YV. Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther Deliv (2011) 2:397-416. doi:10.4155/tde.10.98.
7. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science (2004) 305:200-5. doi:10.1126/science.1100369.
8. Scheinberg D, Rosenblat T, Jurcic J. Antibodies. 5th ed. In: Chabner B, Longo D, editors. Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins (2011). p. 465-94.
9. Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs (2011) 20:75-85. doi:10.1517/13543784.2011.539557.
10. Glennie MJ, van de Winkel JG. Renaissance of cancer therapeutic antibodies. Drug Discov Today (2003) 8:503-10. doi:10.1016/S1359-6446(03)02714-4.
11. Carter P, Smith L, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer (2004) 11:659-87. doi:10.1677/erc.1.00766.
12. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J (2008) 14:154-69. doi:10.1097/PPO.0b013e318172d704.
13. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol (2010) 14:529-37. doi:10.1016/j.cbpa.2010.06.170.
14. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov (2007) 6:349-56. doi:10.1038/nrd2241.
15. Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res (2006) 66:2328-37. doi:10.1158/0008-5472.can-05-2883.
16. Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther (2008) 8:1151-8. doi:10.1517/14712598.8.8.1151.
17. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 346:235-42. doi:10.1056/NEJMoa011795.
18. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer (2006) 106:1569-80. doi:10.1002/cncr.21776.
19. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol (2010) 28:3115-21. doi:10.1200/jco.2009.26.6791.
20. Chao MP. Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma-novel and emerging therapies. Cancer Manag Res (2013) 5:251-69. doi:10.2147/cmar.s34273.
21. Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, et al. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol (2012) 157:438-45. doi:10.1111/j.1365-2141.2012.09086.x.
22. Angiolillo AL, Yu AL, Reaman G, Ingle AM, Secola R, Adamson PC. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr Blood Cancer (2009) 53:978-83. doi:10.1002/pbc.22209.
23. Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol (2005) 23:5044-51. doi:10.1200/jco.2005.13.821.
24. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol (2008) 26:3756-62. doi:10.1200/jco.2007.15.3528.
25. Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM, et al. Reinduction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL) in children, adolescents and young adults: results from Children's Oncology Group (COG) study ADVL04P2. Blood (2013) 122(21):355.
26. Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res (2009) 15:4038-45. doi:10.1158/1078-0432.ccr-08-2808.
27. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res (2011) 17:6389-97. doi:10.1158/1078-0432.ccr-11-1417.
28. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med (2013) 64:15-29. doi:10.1146/annurev-med-050311-201823.
29. Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res (2005) 11:843-52.
30. Sharkey RM, Govindan SV, Cardillo TM, Goldenberg DM. Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther (2012) 11:224-34. doi:10.1158/1535-7163.mct-11-0632.
31. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res (2006) 66:3214-21. doi:10.1158/0008-5472.can-05-3973.
32. Carlson B. Antibody-drug conjugates: where the action is: ADCs-the New Frontier. Biotechnol Healthc (2012) 9:28-31.
33. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res (2004) 10:7063-70. doi:10.1158/1078-0432.ccr-04-0789.
34. Alley SC, Anderson KE. Analytical and bioanalytical technologies for characterizing antibody-drug conjugates. Curr Opin Chem Biol (2013) 17:406-11. doi:10.1016/j.cbpa.2013.03.022.
35. Aplenc R, Alonzo TA, Gerbing RB, Lange BJ, Hurwitz CA, Wells RJ, et al. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol (2008) 26:2390-3295. doi:10.1200/jco.2007.13.0096.
36. Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood (2013) 121:4854-60. doi:10.1182/blood-2013-01-466706.
37. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res (2011) 17:6417-27. doi:10.1158/1078-0432.ccr-11-0486.
38. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood (2013) 122:1455-63. doi:10.1182/blood-2013-03-491506.
39. Hasle H, Abrahamsson J, Forestier E, Ha SY, Heldrup J, Jahnukainen K, et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood (2012) 120:978-84. doi:10.1182/blood-2012-03-416701.
40. Aplenc R, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin (GO) in children with de novo acute myeloid leukemia (AML) improves event-free survival (EFS) by reducing relapse risk-results from the randomized phase III Children's Oncology Group (COG) trial, AAML0531. Blood (2013) 122:355.
41. Gamis A, Aplenc R, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, et al. Gemtuzumab ozogamicin (GO) in children with de novo acute myeloid leukemia (AML) improves event-free survival (EFS) by reducing relapse risk-results from the randomized phase III Children's Oncology Group (COG) trial, AAML0531. Blood (2013) 122:355.
42. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (2012) 379:1508-16. doi:10.1016/s0140-6736(12)60485-1.
43. Balduzzi A, Rossi V, Corral L, Bonanomi S, Longoni D, Rovelli A, et al. Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia (2003) 17:2247-8. doi:10.1038/sj.leu.2403134.
44. Cotter M, Rooney S, O'Marcaigh A, Smith OP. Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia. Br J Haematol (2003) 122:687-8. doi:10.1046/j.1365-2141.2003.04485.x.
45. Zwaan CM, Reinhardt D, Jurgens H, Huismans DR, Hahlen K, Smith OP, et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia (2003) 17:468-70. doi:10.1038/sj.leu.2402749.
46. Cheung KC, Wong LG, Yeung YM. Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg. Leuk Lymphoma (2008) 49:596-7. doi:10.1080/10428190701882161.
47. Chevallier P, Mahe B, Garand R, Talmant P, Harousseau JL, Delaunay J. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression. Int J Hematol (2008) 88:209-11. doi:10.1007/s12185-008-0123-2.
48. Yusuf RZ, Pervez S, Aziz SA, Khurshid M. Flow cytometric analysis of childhood leukemias. J Pak Med Assoc (2001) 51:133-6.
49. Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, Mcbride J, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia (2010) 24:1566-73. doi:10.1038/leu.2010.141.
50. Ogura M, Tobinai K, Hatake K, Uchida T, Kasai M, Oyama T, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci (2010) 101:1840-5. doi:10.1111/j.1349-7006.2010.01601.x.
51. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res (2010) 16:1894-903. doi:10.1158/1078-0432.ccr-09-2980.
52. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol (2012) 30:1822-8. doi:10.1200/jco.2011.38.1756.
53. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol (2012) 13:403-11. doi:10.1016/s1470-2045(11)70386-2.
54. Fayad L, Patel H, Verhoef G, Smith MR, Johnson PWM, Czuczman MS, et al. Safety and clinical activity of the anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) in combination with rituximab in follicular lymphoma or diffuse large B-cell lymphoma: preliminary report of a phase 1/2 study. ASH Annual Meeting Abstracts (2008) 11:266-312. doi:10.1200/JCO.2012.42.7211.
55. Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia (2007) 21:2240-5. doi:10.1038/sj.leu.2404866.
56. Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, et al. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther (2013) 12:1255-65. doi:10.1158/1535-7163.mct-12-1173.
57. Raufi A, Ebrahim AS, Al-Katib A. Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. Cancer Manag Res (2013) 5:225-33. doi:10.2147/cmar.s45957.
58. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res (2011) 17:6448-58. doi:10.1158/1078-0432.ccr-11-0485.
59. Borowitz MJ, Shuster J, Carroll AJ, Nash M, Look AT, Camitta B, et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. Blood (1997) 89:3960-6.
60. Ribrag V, Dupuis J, Tilly H, Morschhauser F, Laine F, Houot R, et al. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res (2014) 20:213-20. doi:10.1158/1078-0432.ccr-13-0580.
61. Younes A, Kim S, Romaguera J, Copeland A, Farial Sde C, Kwak LW, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol (2012) 30:2776-82. doi:10.1200/jco.2011.39.4403.
62. Carol H, Szymanska B, Evans K, Boehm I, Houghton PJ, Smith MA, et al. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin Cancer Res (2013) 19:1795-805. doi:10.1158/1078-0432.ccr-12-3613.
63. Fathi AT, Shah BD, Deangelo DJ, Silverman LB, Cooper TM, Albertson TM, et al. A first-in-human phase 1 study of the antibody-drug conjugate SGN-CD19A in relapsed or refractory B-lineage acute leukemia and highly aggressive lymphoma. Blood (2013) 122:1437. doi:10.3109/10428194.2013.764422.
64. Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res (2011) 17:6398-405. doi:10.1158/1078-0432.ccr-11-0487.
65. Wayne A, Bhojwani D, Richards K, Stetler-Stevenson M, Silverman LB, Jeha S, et al. Complete remissions in 3 of 12 patients with pediatric acute lymphoblastic leukemia (ALL) during phase I testing of the anti-CD22 immunotoxin moxetumomab pasudotox. ASH Annu Meet Abstr (2010) 116:3246.
66. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest (2007) 117:1137-46. doi:10.1172/jci31405.
67. Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res (2007) 13:388-97. doi:10.1158/1078-0432.ccr-06-1734.
68. Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. Lancet (2009) 373:673-83. doi:10.1016/s0140-6736(09)60404-9.
69. Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res (2011) 317:1255-60. doi:10.1016/j.yexcr.2011.03.010.
70. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood (2000) 95:2098-103.
71. Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood (2012) 120:5185-7. doi:10.1182/blood-2012-07-441030.
72. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, Von Stackelberg A. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia (2011) 25:181-4. doi:10.1038/leu.2010.239.
73. Zugmaier G, Handgretinger R, Locatelli F, Rizzari C, Trippett TM, Borkhardt A, et al. A phase 1/2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood (2013) 122:70.
74. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 6:224ra225. doi:10.1126/scitranslmed.3008226.
75. Magnani CF, Tettamanti S, Maltese F, Turazzi N, Biondi A, Biagi E. Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives. Front Oncol (2013) 3:106. doi:10.3389/fonc.2013.00106.
76. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 368:1509-18. doi:10.1056/NEJMoa1215134.
77. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica (2004) 89:753-4.
78. Jaime-Perez JC, Rodriguez-Romo LN, Gonzalez-Llano O, Chapa-Rodriguez A, Gomez-Almaguer D. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol (2009) 144:794-5. doi:10.1111/j.1365-2141.2008.07497.x.
79. Advani AS, Mcdonough S, Coutre S, Wood B, Radich J, Mims M, et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol (2014). doi:10.1111/bjh.12778.